Back

T-Amylo score for the diagnosis of transthyretin cardiac amyloidosis in patients with acute heart failure.

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 5 Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mirta Diez

Instituto Cardiovascular De Buenos Aires, Buenos Aires (Argentina)

7 More presentations in this session

Presentation thumbnail
Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy
Doctor M. Maurer (New York, US)
Abstract Slides Video
Presentation thumbnail
Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis
Mrs E. Lointier (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Right ventricular to pulmonary artery uncoupling is an early predictor of poor outcome in wild-type transthyretin cardiac amyloidosis
Doctor G. Sinigiani (Padua, IT)
Abstract Slides Video
Presentation thumbnail
Impairment of right ventricular to pulmonary artery coupling is associated with worse survival in cardiac amyloidosis
Doctor A. Jakstaite (Hannover, DE)
Abstract Slides Video
Presentation thumbnail
Utility of KAsH score in predicting in-hospital mortality in takotsubo cardiomyopathy
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 5

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Validation of two clinical scores for transthyretin amyloid cardiomyopathy in a mediterranean cohort of patients at risk
thumbnail
Congress Presentation
Validation of two simple scores to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Usefulness of a simple clinical score in identifying increased risk of transthyretin amyloid cardiomyopathy in older patients with unexplained hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources